Pembrolizumab,Cisplatin,Gemcitabine,Pemetrexed
Merck
['kn671', 'ts,perio,i', 'nsclc', 'pembro', 'sclc', 'ts,perio,1']
#asco23 highlights
#kn671 perioperative pembro in stage ii-iiib nsclc
cis-chemo+pembro x4 --&gt; pembro 1yr n=797 (43% scc)
15% stage iiib, egfr/alk 6.5% 1 1yr efs (73% vs 60%), hr 0.58
2 pcr (18% vs 4%)
3 82% surgery, 8% postop xrt do all pts need an extra yr and toxicity of 
Associate Director Community Outreach- DEI- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed